Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
myBinderRelated Content
-
Phase 1/2 Trial of Venetoclax by Dr. Rajshekhar Chakraborty – ASG Webinar – 8/9https://www.youtube.com/watch?v=vP4wvJq5...
-
ISA Virtual Workshop on Gaps in Diagnosis and Management of AL Amyloidosishttps://vimeo.com/645401404...
-
Dr. Rosenzweig Discusses the Standard of Care in Amyloidosishttps://www.youtube.com/watch?v=5lewKqzm...
-
Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 In...Zentalis Pharmaceuticals, Inc. a clinica...
-
Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis PatientsUpdated research regarding the ANDROMEDA...
-
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CMThe 30-month results of the phase 3 ATTR...
-
Progress in Amyloidosis Research: Where Are We Now? – Webinarhttps://www.youtube.com/watch?v=8Yhv87Xo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
